Nanoelectronics driving accuracy, improving turnaround times and increasing yields in cell therapy workflows
The field of cell therapy reached a major milestone with the first CAR T products getting FDA approval: USD Kymriah of Novartis and Yescarta of Kite Pharma. It's likely that this is just the beginning of a wave of T-cell immunotherapy success stories. Now, the focus has turned to clinical adoption. That requires the manufacturing process to be more efficient, upscalable and standardized in order to achieve a safe and efficacious therapy for numerous patients.
The fact that the adoptive therapy consists of live cells, manufactured from T cells derived from the individual patient, represents major challenges for the process development. Today, this has resulted in a long production time (3 weeks to 3 months), high costs and – due to manual intervention at different stages in the process flow – a risk for contamination.
This whitepaper describes some unique results that clearly demonstrate how nanoelectronic sensors can contribute to a standardized, cost-effective and fully automated cell therapy process flow.
To read the full whitepaper, please complete the form
This content is only visible on the desktop version of this website.